Literature DB >> 19768188

The Jeremiah Metzger Lecture: gene therapy for inherited disorders: from Christmas disease to Leber's amaurosis.

Katherine A High1.   

Abstract

This paper will focus on recent developments in the field of gene therapy for inherited disorders. From a historical perspective, this Metzger lecture is a follow-on to one presented by Dr. William Kelley in 1987, entitled "Current Status of Human Gene Therapy" (Transactions Am Clin. Climatol. Assoc. 99:152-169) (1). In 1987, gene transfer studies in human subjects were yet to be undertaken; the first clinical studies, infusion of genetically modified autologous T cells into two young girls with ADA-SCID, would not take place until 1990 (2). Today's lecture will summarize progress since that time in one area, that of in vivo gene transfer for genetic disease. I will describe progress in two areas, gene therapy for the bleeding disorder hemophilia B, and for a subset of retinal degenerative disorders termed Leber's congenital amaurosis, due to mutations in the gene encoding retinal pigment epithelium-specific 65 kilodalton protein (RPE65). This lecture will demonstrate the interconnected nature of progress in these two areas, as careful delineation of the obstacles in hemophilia led to the realization that success could be achieved in Leber's.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19768188      PMCID: PMC2744558     

Source DB:  PubMed          Journal:  Trans Am Clin Climatol Assoc        ISSN: 0065-7778


  59 in total

1.  A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.

Authors:  Salima Hacein-Bey-Abina; Christof von Kalle; Manfred Schmidt; Françoise Le Deist; Nicolas Wulffraat; Elisabeth McIntyre; Isabelle Radford; Jean-Luc Villeval; Christopher C Fraser; Marina Cavazzana-Calvo; Alain Fischer
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

2.  Highly efficient endogenous human gene correction using designed zinc-finger nucleases.

Authors:  Fyodor D Urnov; Jeffrey C Miller; Ya-Li Lee; Christian M Beausejour; Jeremy M Rock; Sheldon Augustus; Andrew C Jamieson; Matthew H Porteus; Philip D Gregory; Michael C Holmes
Journal:  Nature       Date:  2005-04-03       Impact factor: 49.962

3.  Retinal dystrophy of Swedish briard/briard-beagle dogs is due to a 4-bp deletion in RPE65.

Authors:  A Veske; S E Nilsson; K Narfström; A Gal
Journal:  Genomics       Date:  1999-04-01       Impact factor: 5.736

4.  Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.

Authors:  Federico Mingozzi; Yi-Lin Liu; Eric Dobrzynski; Antje Kaufhold; Jian Hua Liu; YuQin Wang; Valder R Arruda; Katherine A High; Roland W Herzog
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

5.  Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors.

Authors:  R O Snyder; C Miao; L Meuse; J Tubb; B A Donahue; H F Lin; D W Stafford; S Patel; A R Thompson; T Nichols; M S Read; D A Bellinger; K M Brinkhous; M A Kay
Journal:  Nat Med       Date:  1999-01       Impact factor: 53.440

6.  Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector.

Authors:  R W Herzog; E Y Yang; L B Couto; J N Hagstrom; D Elwell; P A Fields; M Burton; D A Bellinger; M S Read; K M Brinkhous; G M Podsakoff; T C Nichols; G J Kurtzman; K A High
Journal:  Nat Med       Date:  1999-01       Impact factor: 53.440

7.  Congenital stationary night blindness in the dog: common mutation in the RPE65 gene indicates founder effect.

Authors:  G D Aguirre; V Baldwin; S Pearce-Kelling; K Narfström; K Ray; G M Acland
Journal:  Mol Vis       Date:  1998-10-30       Impact factor: 2.367

8.  De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco.

Authors:  F Vincenti; P Stock
Journal:  Transplant Proc       Date:  2003-05       Impact factor: 1.066

9.  AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

Authors:  Catherine S Manno; Amy J Chew; Sylvia Hutchison; Peter J Larson; Roland W Herzog; Valder R Arruda; Shing Jen Tai; Margaret V Ragni; Arthur Thompson; Margareth Ozelo; Linda B Couto; Debra G B Leonard; Frederick A Johnson; Alan McClelland; Ciaran Scallan; Erik Skarsgard; Alan W Flake; Mark A Kay; Katherine A High; Bertil Glader
Journal:  Blood       Date:  2002-12-19       Impact factor: 22.113

10.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy.

Authors:  Guang-Ping Gao; Mauricio R Alvira; Lili Wang; Roberto Calcedo; Julie Johnston; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

View more
  3 in total

Review 1.  Myopathies Related to Glycogen Metabolism Disorders.

Authors:  Mark A Tarnopolsky
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 2.  Strategies for more rapid translation of cellular therapies for children: a US perspective.

Authors:  Rosa Sanchez; Leslie E Silberstein; Robert W Lindblad; Lisbeth A Welniak; Traci Heath Mondoro; John E Wagner
Journal:  Pediatrics       Date:  2013-07-08       Impact factor: 7.124

3.  Gaucher disease: clinical profile and therapeutic developments.

Authors:  Timothy M Cox
Journal:  Biologics       Date:  2010-12-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.